LiberaTx is using its proprietary extended-release technology to reformulate existing marketed pharmaceuticals to improve treatment outcomes, while reducing the pill burden on patients, with an initial focus on alleviating levodopa-induced dyskinesia in Parkinson’s disease.
LiberaTx Pte Ltd
144 Robinson Road
19-01 Robinson Square
Phone / ContactE: email@example.com
LiberaTx is a spin-out company forged from the material sciences research expertise of Dr Joachim Loo at Nanyang Technological University (Singapore) and Dr Sashi Kesavapany, who has pharma experience in neurodegeneration. LiberaTx seeks to address the unmet medical need of enhancing oral bioavailability of medications for various diseases. Using its proprietary technology, LiberaTx reformulates existing marketed pharmaceuticals to improve treatment outcomes, while reducing the pill burden on patients. In addition, LiberaTx is working with partners to formulate novel biopharmaceuticals and nutraceuticals to promote general health and well-being. The first therapeutic assets are being positioned for alleviating LID in Parkinson’s disease.